https://orcid.org/0000-0002-1281-5296
Figures & data
Figure 1. Flowchart of cohort selection.
Table 1. Baseline characteristics of the study cohort of initiators of LAMA compared with the initiators of LABA, made comparable by fine stratification weighting from probability of treatment propensity scores, with corresponding standardized mean differences.
Figure 2. Kaplan–Meier curves of the one-year cumulative incidence of the first moderate or severe COPD exacerbation comparing initial treatment with LAMA and LABA, after adjustment by inverse probability of treatment weights.
Table 2. Crude and adjusted hazard ratios of a first COPD exacerbation comparing LAMA initiation with LABA initiation in patients with COPD in the first year after treatment initiation, from the as-treated analysis.
Table 3. Crude and adjusted rate ratios of the number of COPD exacerbations comparing LAMA initiation with LABA initiation in patients with COPD in the first year after treatment initiation, estimated using negative binomial regression from the as-treated analysis.
Figure 3. Hazard ratio of a moderate or severe COPD exacerbation with LAMA versus LABA initiation (and 95% confidence limits), as a function of the baseline FEV1 (%), after adjustment by inverse probability of treatment weights. Computed among the 70% subset of patients with available data on FEV1.
Table 4. Crude and adjusted hazard ratios of a first moderate or severe exacerbation associated with LAMA relative to LABA in patients with COPD, with one-year follow-up, from the as-treated analyses, stratified by severity of dyspnea and by prior exacerbations.